All News

Oslo-based anticancer company Algeta has closed a series A financing round totaling €23 million.

Michael Kenward's roundup of new studies, reports and tools for the business of science

Mary Lisbeth D'Amico's first fortnightly funding column reveals how coming out on top in a start-up talent show does not guarantee funding.

Scientists who follow government advice and take up links with industry could find that not everyone will see them in a positive light.

Acquisition gives Roche access to antibody-boosting technology - and possible anti-cancer treatments in the pipeline

How a Swiss university spin-off got to exit in six years - Interview with Joël Jean-Mairet, Chief Executive Officer and Joint Founder, GlycArt.

By mixing academic research with commercial ventures, Sir Richard Friend has returned to the scientific traditions of Faraday and Kelvin. He has also created a new role model for the modern scientist.

Barry Fox thinks that the patent system is deliberately designed to make it hard to find out anything.

Not everyone can produce a Google, Stanford's way of doing business is making other universities look with interest at the revenue possibilities of equity deals.

Once upon a time, there were great businesses with massive central labs that did both product development and basic research. Today, most corporate labs have refocused on applied research. They do not know what they are missing.

No, it has nothing to do with government PR. It's an exotic thing that you can do with electrons.